论文部分内容阅读
采用博莱霉素复制大鼠肺纤维化模型,分别于第2周和第4周分两批处死大鼠,观察Ⅰ、Ⅲ型胶原基因的动态变化。结果显示:在第2周时,博莱霉素组的组织病理学为典型的Ⅲ级肺泡炎表现,成纤维细胞增生。用Proα_1、(Ⅰ)、Proα_1(Ⅲ)肽链的cDNA探针进行DNA-RNA斑点杂交显示,Proα_1(Ⅰ)mRNA表达水平在博莱霉素组、地塞米松治疗组均明显高于正常对照组(P<0.01)。在第4周时,博莱霉素组为典型的Ⅲ～Ⅳ级肺纤维化表现。Proα_1(Ⅰ)mRNA水平在博莱霉素组、地塞米松治疗组均已下降,与正常对照组比较差别无显著性。此外,Proα_(Ⅲ)mRNA水平在第2.4周时均无明显变化。再有,地塞米松对Ⅰ、Ⅲ型胶原基因的表达基本无作用。
Bleomycin-induced rat model of pulmonary fibrosis was used. Rats were sacrificed in two batches at week 2 and week 4 respectively to observe the dynamic changes of type I and type III collagen genes. The results showed that at the second week, the histopathology of bleomycin group was typical of grade Ⅲ alveolitis and fibroblast proliferation. DNA-RNA dot blot showed that Proα_1 (Ⅰ) mRNA expression in the bleomycin group and dexamethasone group were significantly higher than that of the normal control group Group (P <0.01). At week 4, bleomycin group was typical grade Ⅲ ~ Ⅳ pulmonary fibrosis. Proα_1 (Ⅰ) mRNA levels in the bleomycin group, dexamethasone treatment group have decreased, compared with the normal control group no significant difference. In addition, Proα_ (Ⅲ) mRNA levels did not change significantly at the 2nd week. Furthermore, dexamethasone has no effect on the expression of type I and type III collagen genes.